Evidence map›Paper›PMID 36899004›Full record

ArticleNature communications2023

The TINCR ubiquitin-like microprotein is a tumor suppressor in squamous cell carcinoma.

Lucia Morgado-Palacin, Jessie A Brown, Thomas F Martinez, Juana M Garcia-Pedrero, Farhad Forouhar, S Aidan Quinn, Clara Reglero, Joan Vaughan, Yasamin Hajy Heydary, Cynthia Donaldson and 11 more

Open access · goldFull text read
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Eukaryotic Microproteins.Annual review of biochemistry · 2025
    Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Noncanonical microprotein regulation of immunity.Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Review
  16. Microproteins unveiling new dimensions in cancer.Functional & integrative genomics · 2024
    Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 7 institutions in 2 countries.

Lucia Morgado-Palacin *Institute for Cancer Genetics, Columbia University, New York, NY, USA.ORCID 0000-0002-9138-290X
Jessie A Brown *Institute for Cancer Genetics, Columbia University, New York, NY, USA.ORCID 0000-0003-2396-5393
Thomas F MartinezDepartment of Pharmaceutical Sciences, University of California, Irvine, CA, USA.ORCID 0000-0002-4011-8164
Juana M Garcia-PedreroDepartment of Otolaryngology, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain.ORCID 0000-0002-5891-9488
Farhad ForouharProteomics and Macromolecular Crystallography Shared Resource, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA.
S Aidan QuinnInstitute for Cancer Genetics, Columbia University, New York, NY, USA.
Clara RegleroInstitute for Cancer Genetics, Columbia University, New York, NY, USA.
Joan VaughanClayton Foundation Laboratories for Peptide Biology, Salk Institute for Biological Studies, La Jolla, CA, USA.
Yasamin Hajy HeydaryDepartment of Pharmaceutical Sciences, University of California, Irvine, CA, USA.
Cynthia DonaldsonClayton Foundation Laboratories for Peptide Biology, Salk Institute for Biological Studies, La Jolla, CA, USA.
Sandra Rodriguez-PeralesMolecular Cytogenetics Group, Human Cancer Genetics Program, Centro Nacional de Investigaciones Oncológicas (CNIO), 28029, Madrid, Spain.ORCID 0000-0001-7221-3636
Eva AlloncaDepartment of Otolaryngology, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain.ORCID 0000-0002-2532-5421
Rocio Granda-DiazDepartment of Otolaryngology, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain.
Agustin F FernandezInstituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain.
Mario F FragaInstituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain.ORCID 0000-0001-8450-2603
Arianna L KimDepartment of Dermatology, Columbia University Irving Medical Center, New York, NY, USA.
Jorge Santos-JuanesDepartment of Dermatology, Hospital Universitario Central de Asturias (HUCA), Oviedo, Asturias, Spain.
David M OwensDepartment of Dermatology, Columbia University Irving Medical Center, New York, NY, USA.
Juan P RodrigoDepartment of Otolaryngology, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain.
Alan SaghatelianClayton Foundation Laboratories for Peptide Biology, Salk Institute for Biological Studies, La Jolla, CA, USA.ORCID 0000-0002-0427-563X
Adolfo A FerrandoInstitute for Cancer Genetics, Columbia University, New York, NY, USA. af2196@columbia.edu.ORCID 0000-0002-6212-8574
Universidad de Oviedo · ESCancer Genetics (United States) · USSalk Institute for Biological Studies · USColumbia University Irving Medical Center · USUniversity of California, Irvine · USColumbia University · USSpanish National Cancer Research Centre · ES

Funding

Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3M
User Training and OutreachP30GM124165 · NIGMS · CORNELL UNIVERSITY · PI STEVEN E EALICK · 2018 to 2026
$34.2M
National HTX Center: Enabling Access to State-of-the-Art Crystallization CapabilitiesR24GM141256 · NIGMS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI Sarah Elizabeth Johnson Bowman · 2021 to 2026
$6.3M
The Discovery of Human Peptide Encoding GenesR01GM102491 · NIGMS · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI O'SHEA, CLODAGH, SAGHATELIAN, ALAN · 2012 to 2025
$5.5M
Molecular pathways and targeted therapies in human leukemiaR35CA210065 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI FERRANDO, ADOLFO A. · 2017 to 2021
$4.7M
Translational and Precision Medicine Resources Core (TRAP)P30AR069632 · NIAMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MACKAY-WIGGAN, JULIAN M. · 2016 to 2020
$3.9M
Pixel Array Detector for Macromolecular CrystallographyS10OD021527 · OD · CORNELL UNIVERSITY · PI EALICK, STEVEN E · 2016 to 2016
$2.0M
Investigating the role for Utrophin in age-related decline of the Merkel lineageR01AG073874 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI OWENS, DAVID MICHAEL · 2021 to 2025
$2.0M
The Roles of a Novel Microprotein in Wound Healing and CancerK01CA249038 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI MARTINEZ, THOMAS FARID · 2021 to 2025
$688k
Clonal dynamics and chemoresistance mechanisms of minimal residual disease in acute leukemiaK99CA267168 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BROWN, JESSIE ANN · 2022 to 2022
$136k
NCI NIH HHS K01 CA249038NCI NIH HHS K99 CA267168NCI NIH HHS P30 CA013696NCI NIH HHS R35 CA210065NIAMS NIH HHS P30 AR069632NIA NIH HHS R01 AG073874NIGMS NIH HHS P30 GM124165NIGMS NIH HHS R01 GM102491NIGMS NIH HHS R24 GM141256NIH HHS S10 OD021527
6 · The paper itself

Abstract

The TINCR (Terminal differentiation-Induced Non-Coding RNA) gene is selectively expressed in epithelium tissues and is involved in the control of human epidermal differentiation and wound healing. Despite its initial report as a long non-coding RNA, the TINCR locus codes for a highly conserved ubiquitin-like microprotein associated with keratinocyte differentiation. Here we report the identification of TINCR as a tumor suppressor in squamous cell carcinoma (SCC). TINCR is upregulated by UV-induced DNA damage in a TP53-dependent manner in human keratinocytes. Decreased TINCR protein expression is prevalently found in skin and head and neck squamous cell tumors and TINCR expression suppresses the growth of SCC cells in vitro and in vivo. Consistently, Tincr knockout mice show accelerated tumor development following UVB skin carcinogenesis and increased penetrance of invasive SCCs. Finally, genetic analyses identify loss-of-function mutations and deletions encompassing the TINCR gene in SCC clinical samples supporting a tumor suppressor role in human cancer. Altogether, these results demonstrate a role for TINCR as protein coding tumor suppressor gene recurrently lost in squamous cell carcinomas.

Indexed as

Carcinoma, Squamous CellHead and Neck NeoplasmsRNA, Long NoncodingAnimalsCell Line, TumorGene Expression Regulation, NeoplasticGenes, Tumor SuppressorHumansKeratinocytesMiceMicropeptidesUbiquitinMicropeptidesRNA, Long NoncodingUbiquitin

Identifiers

PMID36899004
PMCPMC10006087
OpenAlexW4323834626

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read70
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.